Generally, the way the system works, of course, is that the health care professional has the liberty of filing to both Health Canada and the manufacturer or to either. The regulations for the manufacturer are that whatever we receive, and also whatever we scan in the literature—any source of information with respect to adverse events—should be reported within the specified timelines in the regulations.
Again, the dialogue can be also directly between the health care professional and health care. As has been alluded to by one of my colleagues—I think it was Mr. Schwab—this is an area where we need to be very careful in terms of duplication of information. Obviously, duplication of information can introduce a bias, so we need to be very careful about how this is done.